E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acute blunt soft tissue injuries/contusions of the limbs |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10050584 |
E.1.2 | Term | Contusion |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of Diclofenac sodium topical gel (DSG) 1% applied four times a day compared with placebo in subjects with acute blunt, soft tissue injuries/contusions of the limbs.
|
|
E.2.2 | Secondary objectives of the trial |
To assess the safety of DSG 1% compared with placebo applied four times daily for up to seven days. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female aged 18 years and over. 2. Suffering from fresh impact injury (blunt, traumatic soft tissue injury or contusion) of the upper or the lower limbs, not requiring admittance to hospital. 3. Anticipated time between injury and treatment must be less than 3 hours. 4. Pain-on-movement (POM) ≥ 50 mm on a 100 mm VAS (section 7.5.1). 5. Tenderness reaction of contralateral uninjured site must be at a pressure 1.5 fold higher than at the injured area, with an absolute sensitivity to pain on the contralateral site of at least 2.5 kp/cm2. 6. The size of the traumatisation must be at least 25 cm2 and at most 150 cm2. 7. Satisfactory health as determined by the Investigator based on medical history and physical examination. 8. Give written informed consent before any assessment is performed.
|
|
E.4 | Principal exclusion criteria |
1. Pain medication was taken within the 6 hours that precede randomization. Stable doses of acetylsalicylic acid (≤ 162 mg) taken for at least 30 days prior to the first dose of study medication for non-analgesic reasons may be continued for the duration of the study. Treatment by rest, ice, compression, or elevation (RICE) is permitted. 2. Safety laboratory values with clinically significant abnormalities (as defined in Appendix 14.1 of the protocol). The Investigator will exercise clinical judgment in order to interpret the clinical significance of any abnormal value. 3. Women of child-bearing potential (defined as all women physiologically capable of becoming pregnant) who are not using an acceptable method of contraception defined as: · Surgical sterilization · Hormonal contraception · IUD · Double barrier method · Total abstinence throughout the study at the discretion of the Investigator. Periodic abstinence is NOT an acceptable method of contraception. An acceptable method of contraception must be maintained throughout the study. 4. Pregnant or nursing (lactating) women. 5. Any physical impairment that would influence the study’s efficacy evaluations, in particular POM such as: peripheral or central neurological disease, significant back pain; in case of acute blunt soft tissue injuries of the lower limbs: symptomatic osteoarthritis of the hips, knees, or feet, or any other painful conditions of the lower extremities (e.g., painful nail, wound, corn, or wart), in case of acute blunt soft tissue injuries of the upper limbs: no painful conditions of the upper extremities. 6. Intent to undergo surgery during time of study participation. 7. Any skin lesion or wound or infection in the area to be treated. 8. Topical analgesic or anti-inflammatory treatment over the previous month in the area to be treated. 9. History of allergy (cutaneous or systemic), hypersensitivity, or asthma to any of the following: diclofenac, paracetamol, acetylsalicylic acid, salicylic acid, other NSAID or cyclooxygenase 2-specific inhibitor (COXIB) or known intolerance (cutaneous or systemic) to any of the ingredients in the gel, such as isopropyl alcohol or propylene glycol. 10. Chronic or acute renal or hepatic disorder, inflammatory bowel disease (e.g., Crohn’s disease or ulcerative colitis), or a significant coagulation defect. 11. History of active or suspected esophageal, gastric, pyloric channel, or duodenal ulceration or bleeding within 30 days preceding screening. 12. History of clinically significant cardiovascular, cerebrovascular, metabolic, pulmonary, neurological, hematological, autoimmune, psychiatric or endocrine disorders, including individuals with Type I or Type II diabetes. 13. History of uncontrolled chronic or acute concomitant disease which, in the Investigator’s opinion, would contraindicate study participation or confound interpretation of the results. 14. Uncontrolled psychiatric disease or history of known narcotic, analgesic, or alcohol abuse. 15. Any cognitive impairment that would, in the opinion of the Investigator, preclude study participation or compliance with study procedures (e.g., Alzheimer’s dementia). 16. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases. 17. Previous participation in this clinical study. 18. Participation in any other clinical study within one month prior to screening. 19. Subjects directly or indirectly involved in the execution of this protocol, including employees of the CRO and persons related to them.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy outcome is pain-on-movement (POM) assessed by Visual Analogue Scale (VAS) at Visit 4 (24 hours after initiating treatment).
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
see protocol 6.5.9, p. 23-24and 6.5.11, p. 24 |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 0 |